Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus

Singapore Medical Journal

Volumn 52, Issue 7, 2011, Pages 481-485

  Wijaya, L ^a   Chua, Y Y ^a   Cui, L ^b   Chan, K ^a   Tan, B H ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b MINISTRY OF HEALTH   (Singapore)

Author keywords

H1N1 virus; Influenza; Intensive care unit; Pneumonia; Zanamivir

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT REFERRAL; THROAT CULTURE; VIRUS PNEUMONIA;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; OSELTAMIVIR; PNEUMONIA, VIRAL; SINGAPORE; SURVIVAL ANALYSIS; ZANAMIVIR;

EID: 79961064136     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Baker MG, Wilson N, Huang QS, et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill 2009;14.pii:19319.
2. Donaldson LJ, Rutter PD, Ellis BM, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009; 339:b5213.
3. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19.
4. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-9.
5. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in California. JAMA 2009; 302:1896-902.
6. WHO guidelines for pharmacological management of pandemic (H1N1) 2009influenza and other influenza viruses. February 2010. In: World Health Organization [online]. Available at: www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf. Accessed May 30, 2010.
7. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
8. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34:25-56.
9. GlaxoSmithKline. Important Drug Warning: Safety letter from GlaxoSmithKline regarding Relenza (zanamivir). October 9, 2009. In: US Food and Drug Administration [online]. Available at: www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM186224.pdf. Accessed May 30, 2010.
10. GlaxoSmithKline. Guidance document: zanamivir aqueous solution for compassionate use in serious influenza illness. March 2010: version 4.
11. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-9.
12. WHO Influenza A (H1N1) NA-H274 detailed pyrosequencing protocol for antiviral susceptibility testing. Available at:www.who.int/csr/resources/publications/swineflu/NA_DetailedPyrosequencing_20090513.pdf. Accessed July 2, 2010.
13. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin infect Dis 2010; 50:1493-6.
14. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362:88-9.
15. Härter G, Zimmermann G, Maier L, et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 2010; 50:1249-51.
16. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357-63.
17. Wildschut ED, de Hoog M, Ahsman MJ, et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One 2010; 5:e10938.
18. Emergency use authorization of Peramivir IV: fact sheet for healthcare providers. In: Centers for Disease Control and Prevention 2009 [online] Available at: www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationfo patientsandproviders/ucm187811.pdf. Accessed July 27, 2010.
19. Mancuso CE, Gabay MP, Steinke LM, Vanosdol SJ. Peramivir: An intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza. Ann Pharmacother 2010; 44:1240-9.
20. Chew FT, Doraisingham S, Ling AE, Kumarasinghe G, Lee BW. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 1998; 121:121-8.
21. Leo YS, Lye DC, Chow A. Influenza in the tropics. Lancet Infect Dis 2009; 9:457-8.
22. Weekly publication of statistics on local infectious disease situation. Weekly infectious disease bulletin. In: Ministry of Health Singapore [online]. Available at: www.moh.gov.sg/mohcorp/uploadedFiles/Statistics/Infectious_Diseases_Bulletin/2010/2010_week_07.pdf. Accessed June 10, 2010.
23. Doraisingham S, Ling AE. Patterns of viral respiratory tract infections in Singapore. Ann Acad Med Singapore 1986; 15:9-14.